Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 4/2019

01-04-2019 | Original Article

Which factors can aid clinicians to identify a risk of pain during the following month in patients with bone metastases? A longitudinal analyses

Authors: Ragnhild Habberstad, M. J. Hjermstad, C. Brunelli, S. Kaasa, M. I. Bennett, K. Pardon, P. Klepstad

Published in: Supportive Care in Cancer | Issue 4/2019

Login to get access

Abstract

Purpose

Explore clinical factors associated with higher pain intensity and future pain in patients with bone metastases to identify patients who can benefit from closer follow-up or pain-modifying interventions.

Methods

This is a secondary analysis of 606 patients with bone metastases included in a multicenter longitudinal study. The dependent variables were “average pain” and “worst pain” in the last 24 h (0–10 NRS). Twenty independent variables with potential association to pain intensity were selected based on previous literature. Cross-sectional analyses were performed with multiple linear regression to explore factors associated with pain intensity at baseline. Longitudinal data were analyzed with a generalized equation models to explore current factors associated with pain intensity at the next visit in 1 month.

Results

Current pain intensity (p < 0.001), sleep disturbances (p 0.01 and 0.006), drowsiness (p 0.003 and 0.033) and male gender (p 0.045 and 0.001) were associated with higher average and worst pain intensity in 1 month. In addition, breakthrough pain was related to higher worst pain intensity (p 0.003) in 1 month. The same variables were also associated with higher average pain intensity at baseline.

Conclusion

Higher current pain intensity, sleep disturbances, drowsiness, male gender, and breakthrough pain are factors associated with higher pain intensity in patients with bone metastases at the next follow-up in 1 month. These factors should be assessed in clinical practice and may aid clinicians in identifying patients that can benefit from closer follow-up or interventions to prevent lack of future pain control.

Trial registration in clinicaltrials.​gov

NCT01362816.
Literature
1.
Bruera E, Kuehn N, Miller MJ, Selmser P, Macmillan K (1991) The Edmonton symptom assessment system (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care 7:6–9PubMedCrossRef
2.
Chow E, Zeng L, Salvo N, Dennis K, Tsao M, Lutz S (2012) Update on the systematic review of palliative radiotherapy trials for bone metastases. Clin Oncol 24:112–124CrossRef
3.
Clare C, Royle D, Saharia K, Pearse H, Oxberry S, Oakley K, Allsopp L, Rigby AS, Johnson MJ (2005) Painful bone metastases: a prospective observational cohort study. Palliat Med 19:521–525CrossRefPubMed
4.
Cleeland CS (2006) The measurement of pain from metastatic bone disease: capturing the patient’s experience. Clin Cancer Res 12:6236s–6242sCrossRefPubMed
5.
Coleman RE (2006) Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 12:6243s–6249sCrossRefPubMed
6.
Delaney A, Fleetwood-Walker SM, Colvin LA, Fallon M (2008) Translational medicine: cancer pain mechanisms and management. Br J Anaesth 101:87–94CrossRefPubMed
7.
Delgado-Guay M, Yennurajalingam S, Parsons H, Palmer JL, Bruera E (2011) Association between self-reported sleep disturbance and other symptoms in patients with advanced cancer. J Pain Symptom Manag 41:819–827CrossRef
8.
Evans C, McCarthy M (1985) Prognostic uncertainty in terminal care: can the Karnofsky index help? Lancet 1:1204–1206CrossRefPubMed
9.
Fainsinger RL, Fairchild A, Nekolaichuk C, Lawlor P, Lowe S, Hanson J (2009) Is pain intensity a predictor of the complexity of cancer pain management? J Clin Oncol 27:585–590CrossRefPubMed
10.
Fayers PM, Hjermstad MJ, Ranhoff AH, Kaasa S, Skogstad L, Klepstad P, Loge JH (2005) Which mini-mental state exam items can be used to screen for delirium and cognitive impairment? J Pain Symptom Manag 30:41–50CrossRef
11.
Groenvold M, Petersen MA, Aaronson NK, Arraras JI, Blazeby JM, Bottomley A, Fayers PM, de Graeff A, Hammerlid E, Kaasa S, Sprangers MA, Bjorner JB, Group EQoL (2006) The development of the EORTC QLQ-C15-PAL: a shortened questionnaire for cancer patients in palliative care. Eur J Cancer 42:55–64CrossRefPubMed
12.
Hagen NA, Stiles C, Nekolaichuk C, Biondo P, Carlson LE, Fisher K, Fainsinger R (2008) The Alberta Breakthrough Pain Assessment Tool for cancer patients: a validation study using a delphi process and patient think-aloud interviews. J Pain Symptom Manag 35:136–152CrossRef
13.
Hjermstad MJ, Aass N, Aielli F, Bennett M, Brunelli C, Caraceni A, Cavanna L, Fassbender K, Feio M, Haugen DF, Jakobsen G, Laird B, Lohre ET, Martinez M, Nabal M, Noguera-Tejedor A, Pardon K, Pigni A, Piva L, Porta-Sales J, Rizzi F, Rondini E, Sjogren P, Strasser F, Turriziani A, Kaasa S, European Palliative Care Cancer Symptoms (2016) Characteristics of the case mix, organisation and delivery in cancer palliative care: a challenge for good-quality research BMJ Support Palliat Care
14.
Holtan A, Aass N, Nordoy T, Haugen DF, Kaasa S, Mohr W, Kongsgaard UE (2007) Prevalence of pain in hospitalised cancer patients in Norway: a national survey. Palliat Med 21:7–13CrossRefPubMed
15.
Im EO, Chee W (2006) Evaluation of the decision support computer program for cancer pain management. Oncol Nurs Forum 33:977–982CrossRefPubMed
16.
17.
Kerba M, Wu JS, Duan Q, Hagen NA, Bennett MI (2010) Neuropathic pain features in patients with bone metastases referred for palliative radiotherapy. J Clin Oncol 28:4892–4897CrossRefPubMed
18.
19.
Knudsen AK, Brunelli C, Klepstad P, Aass N, Apolone G, Corli O, Montanari M, Caraceni A, Kaasa S (2012) Which domains should be included in a cancer pain classification system? Analyses of longitudinal data. Pain 153:696–703CrossRefPubMed
20.
Knudsen AK, Brunelli C, Kaasa S, Apolone G, Corli O, Montanari M, Fainsinger R, Aass N, Fayers P, Caraceni A, Klepstad P, European Palliative Care Research C, European Pharmacogenetic S (2011) Which variables are associated with pain intensity and treatment response in advanced cancer patients?—Implications for a future classification system for cancer pain. Eur J Pain 15:320–327CrossRefPubMed
21.
Laird BJ, Walley J, Murray GD, Clausen E, Colvin LA, Fallon MT (2011) Characterization of cancer-induced bone pain: an exploratory study. Support Care Cancer 19:1393–1401CrossRefPubMed
22.
Lechner B, Chow S, Chow R, Zhang L, Tsao M, Danjoux C, Barnes E, DeAngelis C, Vuong S, Ganesh V, Chow E (2016) The incidence of neuropathic pain in bone metastases patients referred for palliative radiotherapy. Radiother Oncol 118:557–561CrossRefPubMed
23.
24.
Lynch ME, Fischbach C (2014) Biomechanical forces in the skeleton and their relevance to bone metastasis: biology and engineering considerations. Adv Drug Deliv Rev 79-80:119–134CrossRefPubMed
25.
26.
27.
Mercadante S, Adile C, Ferrera P, Masedu F, Valenti M, Aielli F (2017) Sleep disturbances in advanced cancer patients admitted to a supportive/palliative care unit. Support Care Cancer 25:1301–1306CrossRefPubMed
28.
Mercadante S, Portenoy RK (2016) Breakthrough cancer pain: twenty-five years of study. Pain 157:2657–2663CrossRefPubMed
29.
Meuser T, Pietruck C, Radbruch L, Stute P, Lehmann KA, Grond S (2001) Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology. Pain 93:247–257CrossRefPubMed
30.
Miaskowski C (2004) Gender differences in pain, fatigue, and depression in patients with cancer. J Natl Cancer Inst Monogr 2004:139–143CrossRef
31.
Middlemiss T, Laird BJ, Fallon MT (2011) Mechanisms of cancer-induced bone pain. Clin Oncol 23:387–392CrossRef
32.
Nekolaichuk CL, Fainsinger RL, Lawlor PG (2005) A validation study of a pain classification system for advanced cancer patients using content experts: the Edmonton Classification System for Cancer Pain. Palliat Med 19:466–476CrossRefPubMed
33.
Nekolaichuk CL, Fainsinger RL, Aass N, Hjermstad MJ, Knudsen AK, Klepstad P, Currow DC, Kaasa S, European Palliative Care Research C (2013) The Edmonton Classification System for Cancer Pain: comparison of pain classification features and pain intensity across diverse palliative care settings in eight countries. J Palliat Med 16:516–523CrossRefPubMed
34.
Oh SY, Shin SW, Koh SJ, Bae SB, Chang H, Kim JH, Kim HJ, Hong YS, Park KU, Park J, Lee KH, Lee NR, Lee JL, Jang JS, Hong DS, Lee SS, Baek SK, Choi DR, Chung J, Oh SC, Han HS, Yun HJ, Sym SJ, Yoon SY, Choi IS, Shim BY, Kang SY, Kim SR, Kim HJ (2017) Multicenter, cross-sectional observational study of the impact of neuropathic pain on quality of life in cancer patients. Support Care Cancer 25(12):3759–3767CrossRefPubMedPubMedCentral
35.
Pan W (2001) Akaike’s information criterion in generalized estimating equations. Biometrics 57:120–125CrossRefPubMed
36.
Pina P, Sabri E, Lawlor PG (2015) Characteristics and associations of pain intensity in patients referred to a specialist cancer pain clinic. Pain Res Manag 20:249–254CrossRefPubMedPubMedCentral
37.
Roodman GD (2012) Genes associate with abnormal bone cell activity in bone metastasis. Cancer Metastasis Rev 31:569–578CrossRefPubMed
38.
Scarpi E, Calistri D, Klepstad P, Kaasa S, Skorpen F, Habberstad R, Nanni O, Amadori D, Maltoni M (2014) Clinical and genetic factors related to cancer-induced bone pain and bone pain relief. Oncologist 19:1276–1283CrossRefPubMedPubMedCentral
39.
van den Beuken-van Everdingen MH, Hochstenbach LM, Joosten EA, Tjan-Heijnen VC, Janssen DJ (2016) Update on prevalence of pain in patients with cancer: systematic review and meta-analysis. J Pain Symptom Manag 51(1070–1090):e1079
40.
van der Vliet QM, Paulino Pereira NR, Janssen SJ, Hornicek FJ, Ferrone ML, Bramer JA, van Dijk CN, Schwab JH (2017) What factors are associated with quality of life, pain interference, anxiety, and depression in patients with metastatic bone disease? Clin Orthop Relat Res 475:498–507CrossRefPubMed
41.
von Moos R, Costa L, Ripamonti CI, Niepel D, Santini D (2017) Improving quality of life in patients with advanced cancer: targeting metastatic bone pain. Eur J Cancer 71:80–94CrossRef
42.
Winters-Stone KM, Schwartz A, Nail LM (2010) A review of exercise interventions to improve bone health in adult cancer survivors. J Cancer Surviv 4:187–201CrossRefPubMed
43.
Wu JS, Beaton D, Smith PM, Hagen NA (2010) Patterns of pain and interference in patients with painful bone metastases: a brief pain inventory validation study. J Pain Symptom Manag 39:230–240CrossRef
44.
Wu JS, Wong R, Johnston M, Bezjak A, Whelan T, Cancer Care Ontario Practice Guidelines Initiative Supportive Care G (2003) Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases. Int J Radiat Oncol Biol Phys 55:594–605CrossRefPubMed
45.
Zeger SL, Liang KY (1986) Longitudinal data analysis for discrete and continuous outcomes. Biometrics 42:121–130CrossRefPubMed
Metadata
Title
Which factors can aid clinicians to identify a risk of pain during the following month in patients with bone metastases? A longitudinal analyses
Authors
Ragnhild Habberstad
M. J. Hjermstad
C. Brunelli
S. Kaasa
M. I. Bennett
K. Pardon
P. Klepstad
Publication date
01-04-2019
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 4/2019
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-018-4405-9

Other articles of this Issue 4/2019

Supportive Care in Cancer 4/2019 Go to the issue

Original Article

Modeling symptom drivers of oral intake in long-term head and neck cancer survivors

Original Article

Urine cultures at the onset of febrile neutropenia rarely impact antibiotic management in asymptomatic adult cancer patients

Correction

Correction to: Influence of cancer and acute inflammatory disease on taste perception: a clinical pilot study

Original Article

Can levocarnitine supplementation improve fatigue caused by sunitinib as a treatment for renal cell carcinoma? A single-center prospective pilot study

Original Article

Prognostic value of paravertebral muscle density in patients with spinal metastases from gastrointestinal cancer

Original Article

Enhancing behavioral change among lung cancer survivors participating in a lifestyle risk reduction intervention: a qualitative study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits